Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»

Версія за 05:25, 19 січня 2018

Manuscript Uring {the right|the proper|the correct|the best|the appropriate received on October 17, 2013. A detailed explanation on the statistical strategies is out there within the On line Supplement.Final results Baseline characteristicsThe median age on the whole cohort was 58 years (variety, 27-93 years), as well as the percentage of individuals older than 70 years was 22 . In line with D ner's hierarchical model, 17/221 (eight ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when incredibly sensitive immunophenotypic or molecular techniques are employed to appear for residual disease. These sufferers are deemed to possess achieved a minimal residual illness (MRD) damaging status.17-20 Many phase II trials have demonstrated that sufferers attaining MRD negativity have a signif-icantly longer survival than individuals who remain MRD good, and this really is accurate for individuals treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) recently revealed that individuals getting MRD negativity had substantially longer progression-free and overall survivals, irrespectively in the remedy received.18 Unfortunately, even so, some of these studies have been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from treatment initiation.27 Furthermore, there are lots of caveats for the use of MRD evaluation in individuals with CLL.28 1st, CLL remains incurable and at the least 30 of sufferers who achieve MRD negativity after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later encounter a illness relapse inside 5 years.18 Secondly, as opposed to the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity just after an initial MRD-negative response compared to therapy in the time of clinical relapse. In fact, pretty couple of studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and a few of the approaches tested, although productive, resulted in important toxicity.33-35 Thirdly, it might be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers since, as an illustration, patients with a 17p014 Ferrata Storti Foundation. This can be an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion possess a higher probability of remaining MRD-positive soon after therapy in comparison to individuals without the need of this chromosome abnormality.18 For all these motives, present recommendations for the management of patients with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this information in thoughts, we retrospectively evaluated the impact of MRD on the outcome of individuals with CLL receiving any front-line therapy within the context of an incredibly detailed prognostic evaluation, like recently described recurrent gene mutations.survival and all round survival have been calculated applying a landmark analysis. All calculations were performed making use of either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 have been thought of statistically important.